OTraces Inc.
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite communications ” that is being applied to biological cancer testing for the first time. The result has been cancer blood tests with extraordinary accuracy and precision. OTraces is the only this method can access the diagnostic content of the TME (tumor microenvironment), and that can determine tumor progression non-invasively and in real time. OTraces can boost predictive power and optimize biomarker performance of any correlative diagnostic test ” DNA- and RNA-based approaches included. This technology can detect cancer as early as Stage 0-1 tumors“ at low cost while using ordinary instrumentation deployed in labs and clinics worldwide.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2008
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Convergence of Artificial Intelligence (AI), Machine Learning and Proteins Active in the Tumor Microenvironment
OTraces’ founder and CEO Keith Lingenfelter has been an in vitro diagnostic industry innovator and pioneer for many years. As a senior officer at IGEN International, Inc. in the ‘90s, he developed electrochemiluminesene (ECL) as a diagnostic tool, which was sold to Roche for $1.5 billion in 2003 where it became the nucleus for Roche’ successful ElecsysTM platform for volume screening platform.
Starting with the founding of OTraces in 2008, Mr. Lingenfelter has led in the development of OTrace’s core technology which apples the principals of math- and physics-based measure science to in vitro cancer detection and high volume screening for the first time.